-+ 0.00%
-+ 0.00%
-+ 0.00%

Regenxbio Meets Primary Endpoint in Duchenne Muscular Dystrophy Study, Swings to 1Q Loss -- Update

Dow Jones·05/14/2026 12:33:00

Please log in to view news